摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(3-(9-fluorenylmethoxycarbonyl)amino-4-methoxybenzoyl)-1-(3,4,5-trimethoxyphenyl)-2-aminoethanol | 256935-70-3

中文名称
——
中文别名
——
英文名称
N-(3-(9-fluorenylmethoxycarbonyl)amino-4-methoxybenzoyl)-1-(3,4,5-trimethoxyphenyl)-2-aminoethanol
英文别名
9H-fluoren-9-ylmethyl N-[5-[[2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]carbamoyl]-2-methoxyphenyl]carbamate
N-(3-(9-fluorenylmethoxycarbonyl)amino-4-methoxybenzoyl)-1-(3,4,5-trimethoxyphenyl)-2-aminoethanol化学式
CAS
256935-70-3
化学式
C34H34N2O8
mdl
——
分子量
598.653
InChiKey
KOXLWICVBRGVHT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    44
  • 可旋转键数:
    12
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    125
  • 氢给体数:
    3
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-(3-(9-fluorenylmethoxycarbonyl)amino-4-methoxybenzoyl)-1-(3,4,5-trimethoxyphenyl)-2-aminoethanolmethoxycarbonylsulfamoyl-triethylammmonium hydroxide 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以97%的产率得到{2-Methoxy-5-[5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-oxazol-2-yl]-phenyl}-carbamic acid 9H-fluoren-9-ylmethyl ester
    参考文献:
    名称:
    New Antimitotic Agents with Activity in Multi-Drug-Resistant Cell Lines and in Vivo Efficacy in Murine Tumor Models
    摘要:
    During a screen for compounds that could inhibit cell proliferation, a series of new tubulin-binding compounds was identified with the discovery of oxadiazoline 1 (A-105972). This compound showed good cytotoxic activity against non-multi-drug-resistant and multi-drug-resistant cancer cell lines, but its utility in vivo was limited by a short half-life. Medicinal chemistry efforts led to the discovery of indolyloxazoline 22g (A-259745), which maintained all of the in vitro activity seen with oxadiazoline 1, but also demonstrated a better pharmacokinetic profile, and dose-dependent in vivo activity. Over a 28 day study, indolyloxazoline 22g increased the life span of tumor-implanted mice by up to a factor of 3 upon oral dosing. This compound, and others of its structural class, may prove to be useful in the development of new chemotherapeutic agents to treat human cancers.
    DOI:
    10.1021/jm010231w
  • 作为产物:
    描述:
    (9H-芴-9-基)甲基 2,5-二氧代吡咯烷-1-羧酸N-甲基吗啉 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 四氢呋喃N,N-二甲基甲酰胺丙酮 为溶剂, 反应 18.0h, 生成 N-(3-(9-fluorenylmethoxycarbonyl)amino-4-methoxybenzoyl)-1-(3,4,5-trimethoxyphenyl)-2-aminoethanol
    参考文献:
    名称:
    New Antimitotic Agents with Activity in Multi-Drug-Resistant Cell Lines and in Vivo Efficacy in Murine Tumor Models
    摘要:
    During a screen for compounds that could inhibit cell proliferation, a series of new tubulin-binding compounds was identified with the discovery of oxadiazoline 1 (A-105972). This compound showed good cytotoxic activity against non-multi-drug-resistant and multi-drug-resistant cancer cell lines, but its utility in vivo was limited by a short half-life. Medicinal chemistry efforts led to the discovery of indolyloxazoline 22g (A-259745), which maintained all of the in vitro activity seen with oxadiazoline 1, but also demonstrated a better pharmacokinetic profile, and dose-dependent in vivo activity. Over a 28 day study, indolyloxazoline 22g increased the life span of tumor-implanted mice by up to a factor of 3 upon oral dosing. This compound, and others of its structural class, may prove to be useful in the development of new chemotherapeutic agents to treat human cancers.
    DOI:
    10.1021/jm010231w
点击查看最新优质反应信息

文献信息

  • Oxazoline antiproliferative agents
    申请人:Abbott Laboratories
    公开号:US06228868B1
    公开(公告)日:2001-05-08
    Compounds having Formula I are useful for treating cancer. Also disclosed are pharmaceutical compositions comprising compounds of Formula I, and methods of treating cancer in a mammal.
    具有化学式I的化合物对治疗癌症有用。还公开了包含化学式I化合物的药物组合物,以及在哺乳动物中治疗癌症的方法。
  • US6228868B1
    申请人:——
    公开号:US6228868B1
    公开(公告)日:2001-05-08
查看更多